Les antagonistes de la cholécystokinine: futurs antalgiques?
Douleur et Analgésie · 1997
DOI: 10.1007/bf03003146 ↗At a glance
Journal article in Douleur et Analgésie, 1997. Written by C. Mann. Cited 1 times so far (Crossref); 22 references.
Abstract (original language)
Cholecystokinin (CCK) is located in the brain and the spinal cord. CCK acts as a neuromediator and produces various biological effects that are mediated by two receptors: CCK-A and CCK-B, the predominant form found in the central nervous system. Electrophysiological and behavioural studies suggest the existence of regulatory mechanism between CCK and opioid systems in the control of pain. Thus, it has been proposed that CCK could act as an endogenous opiate and play a role in the development of morphine tolerance. In contrast, administration of a CCK-B receptor antagonist may enhance the antinociceptive effect of morphine. Experimental and clinical studies indicate the possibility for the therapeutic use of selective and specific CCK-B receptor antagonists as co-analgesics with morphine in postoperative period or in patient with intractable pain.
Cite
APA
Mann, C. (1997). Les antagonistes de la cholécystokinine: futurs antalgiques?. Douleur et Analgésie. https://doi.org/10.1007/bf03003146
Vancouver
Mann C. Les antagonistes de la cholécystokinine: futurs antalgiques?. Douleur et Analgésie. 1997. doi:10.1007/bf03003146
BibTeX
@article{Mann1997,
author = {Mann, C.},
title = {Les antagonistes de la cholécystokinine: futurs antalgiques?},
journal = {Douleur et Analgésie},
year = {1997},
doi = {10.1007/bf03003146}
}
EUVIMED